Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes-Peter Stasch

Showing results (1-10 of 128) with videos related to

Pageof 13
Sort By:
Circulation|September 24, 2004
Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibitionErwin Bischoff, Johannes-Peter Stasch
Respiratory Medicine|March 26, 2017
Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidencePeter Sandner, Johannes Peter Stasch
Handbook of Experimental Pharmacology|October 5, 2013
Soluble guanylate cyclase stimulators in pulmonary hypertensionJohannes-Peter Stasch, Oleg V Evgenov
Handbook of Experimental Pharmacology|December 18, 2008
NO-independent, haem-dependent soluble guanylate cyclase stimulatorsJohannes-Peter Stasch, Adrian J Hobbs
Methods in Molecular Biology (Clifton, N.J.)|May 28, 2013
Receptor binding assay for NO-independent activators of soluble guanylate cyclasePeter M Schmidt, Johannes-Peter Stasch
Current Opinion in Pharmacology|February 4, 2015
Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidenceJohannes-Peter Stasch, Jens Schlossmann, Berthold Hocher
Biochemical and Biophysical Research Communications|April 12, 2002
BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclaseMarkus Koglin, Johannes-Peter Stasch, Sönke Behrends
Circulation|May 25, 2011
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary diseaseJohannes-Peter Stasch, Pál Pacher, Oleg V Evgenov
Analytical Biochemistry|March 14, 2003
Receptor binding assay for nitric oxide- and heme-independent activators of soluble guanylate cyclasePeter Schmidt, Matthias Schramm, Henning Schröder, et al.
Handbook of Experimental Pharmacology|November 11, 2015
Translational In Vivo Models for Cardiovascular DiseasesDaniela Fliegner, Christoph Gerdes, Jörg Meding, et al.
Pageof 13

Showing results (1-10 of 128) with videos related to

Sort By:
Pageof 13
Circulation|September 24, 2004
Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibitionErwin Bischoff, Johannes-Peter Stasch
Respiratory Medicine|March 26, 2017
Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidencePeter Sandner, Johannes Peter Stasch
Handbook of Experimental Pharmacology|October 5, 2013
Soluble guanylate cyclase stimulators in pulmonary hypertensionJohannes-Peter Stasch, Oleg V Evgenov
Handbook of Experimental Pharmacology|December 18, 2008
NO-independent, haem-dependent soluble guanylate cyclase stimulatorsJohannes-Peter Stasch, Adrian J Hobbs
Methods in Molecular Biology (Clifton, N.J.)|May 28, 2013
Receptor binding assay for NO-independent activators of soluble guanylate cyclasePeter M Schmidt, Johannes-Peter Stasch
Current Opinion in Pharmacology|February 4, 2015
Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidenceJohannes-Peter Stasch, Jens Schlossmann, Berthold Hocher
Biochemical and Biophysical Research Communications|April 12, 2002
BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclaseMarkus Koglin, Johannes-Peter Stasch, Sönke Behrends
Circulation|May 25, 2011
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary diseaseJohannes-Peter Stasch, Pál Pacher, Oleg V Evgenov
Analytical Biochemistry|March 14, 2003
Receptor binding assay for nitric oxide- and heme-independent activators of soluble guanylate cyclasePeter Schmidt, Matthias Schramm, Henning Schröder, et al.
Handbook of Experimental Pharmacology|November 11, 2015
Translational In Vivo Models for Cardiovascular DiseasesDaniela Fliegner, Christoph Gerdes, Jörg Meding, et al.
Pageof 13